IOVANCE BIOTHERAPEUTICS, INC. Increase (Decrease) in Inventories
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Increase (Decrease) in Inventories of $5.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-06
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was $177.00K.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $4.93M, a 64.36% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was $4.00M, a 78.86% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was $3.02M, a 69.34% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2025 was $14.21M, a 67.98% decline from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2024 was $44.38M, a 338.64% increase from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2023 was $10.12M.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 3 month as first filed | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 6 month as first filed | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 9 month as first filed | Increase (Decrease) in Inventories 12 month | Increase (Decrease) in Inventories 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $177.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.11M 10-Q · filed 2026-08-06 | $9.11M derived: sum of 3 quarters · filed 2026-08-06 | $12.13M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $4.93M 10-Q · filed 2026-05-07 | $8.93M derived: sum of 2 quarters · filed 2026-05-07 | $11.96M derived: sum of 3 quarters · filed 2026-05-07 | $5.31M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.02M derived: sum of 2 quarters · filed 2026-02-24 | $377.00K derived: sum of 3 quarters · filed 2026-08-06 | $14.21M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $3.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.62M derived: sum of 2 quarters · filed 2026-08-06 | $10.21M 10-Q · filed 2025-11-06 | $29.14M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$6.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $7.19M 10-Q · filed 2026-08-06 | $7.03M 10-Q · filed 2025-08-07 | $26.11M derived: sum of 3 quarters · filed 2026-08-06 | $35.98M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $13.83M 10-Q · filed 2026-05-07 | $13.97M 10-Q · filed 2025-05-08 | $32.76M derived: sum of 2 quarters · filed 2026-05-07 | $42.62M derived: sum of 3 quarters · filed 2026-05-07 | $51.48M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $18.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $28.79M derived: sum of 2 quarters · filed 2026-02-24 | $37.65M derived: sum of 3 quarters · filed 2026-02-24 | $44.38M 10-K · filed 2026-02-24 | $39.92M 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $9.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $18.72M derived: sum of 2 quarters · filed 2025-11-06 | $25.45M 10-Q · filed 2025-11-06 | $26.47M 10-Q · filed 2024-11-07 | $26.38M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2024-06-30 | $8.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $15.59M 10-Q · filed 2025-08-07 | $16.52M derived: sum of 3 quarters · filed 2026-02-24 | $16.16M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $6.74M 10-Q · filed 2025-05-08 | $7.66M derived: sum of 2 quarters · filed 2026-02-24 | $7.30M derived: sum of 3 quarters · filed 2026-02-24 | $16.85M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $923.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $569.00K derived: sum of 2 quarters · filed 2026-02-24 | $10.12M derived: sum of 3 quarters · filed 2026-02-24 | $10.12M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | -$354.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $9.20M derived: sum of 2 quarters · filed 2024-11-07 | $9.20M 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | $9.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $9.55M 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | |||||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||||||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |